NewAmsterdam Pharma (NAMS) Equity Average (2023 - 2025)
NewAmsterdam Pharma (NAMS) has disclosed Equity Average for 3 consecutive years, with $705.8 million as the latest value for Q4 2025.
- Quarterly Equity Average rose 24.21% to $705.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $705.8 million through Dec 2025, up 24.21% year-over-year, with the annual reading at $720.5 million for FY2025, 37.77% up from the prior year.
- Equity Average hit $705.8 million in Q4 2025 for NewAmsterdam Pharma, down from $753.3 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $777.9 million in Q2 2025 to a low of $310.1 million in Q4 2023.
- Historically, Equity Average has averaged $516.7 million across 3 years, with a median of $423.0 million in 2023.
- Biggest five-year swings in Equity Average: decreased 21.57% in 2024 and later soared 119.2% in 2025.
- Year by year, Equity Average stood at $310.1 million in 2023, then skyrocketed by 83.22% to $568.2 million in 2024, then rose by 24.21% to $705.8 million in 2025.
- Business Quant data shows Equity Average for NAMS at $705.8 million in Q4 2025, $753.3 million in Q3 2025, and $777.9 million in Q2 2025.